Patient & Survivor Care
News from the FDA/CDC
FDA Approves Lymphir for R/R Cutaneous T-Cell Lymphoma
The immunotherapy is a reformulation of denileukin diftitox that was initially approved for certain patients with persistent or recurrent...
Feature
Immunotherapy May Be Overused in Dying Patients With Cancer
“There are patients who are getting immunotherapy who shouldn’t,” according to a surgical oncologist from Yale.
From the Journals
Modest Gains Shown in Breast Cancer Immunotherapy Trials
Researchers evaluated 331 immunotherapy trials, enrolling nearly 50,000 patients with breast cancer.
From the Journals
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
Researchers evaluated whether greater reductions in grade 3 chemotherapy-related toxicities occurred with geriatric assessment-driven...
From the Journals
Tool Can Help Predict Futile Surgery in Pancreatic Cancer
Researchers evaluate patients with anatomically resectable pancreatic ductal adenocarcinoma who underwent pancreatic resection.
From the Journals
Metastasis-Directed Therapy Ups PFS in Pancreatic Cancer
Researchers randomize patients with pancreatic cancer to receive MDT plus systemic therapy or systemic therapy alone.
News from the FDA/CDC
FDA Approves First Engineered Cell Therapy for a Solid Tumor
This T-cell receptor therapy modifies existing receptors to recognize an array of antigens on the surface of cancer cells.
News from the FDA/CDC
FDA Expands Dostarlimab-gxly Approval for Endometrial Cancer
‘This is the only immuno-oncology treatment regimen that has shown a statistically significant overall survival benefit for the full patient...
News from the FDA/CDC
FDA Expands Darzalex Faspro Indication in Myeloma
The approval followed priority review and was based on efficacy and safety findings from the open-label PERSEUS trial.
From the Journals
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
Researchers analyze data from more than 17,000 patients who died of cancer between 2012 and 2017.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.